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BACKGROUND. Disparities in cancer outcome among different subsets of the Amer-
ican population related to ethnic background have been well documented. Clinical
trials represent the most powerful strategy for improving cancer treatments, but
racial and ethnic minority patients are frequently underrepresented among pa-
tients accrued to these protocols. Proof of comparable efficacy for a promising
cancer therapy in different groups of patients requires diversity in the clinical trial
populations so that study results will be generalizable. Appropriate targets for
accrual of minority ethnicity patients have not previously been defined.
METHODS. The National Cancer Database (NCDB) is maintained jointly by the
American Cancer Society and the American College of Surgeons. Information
submitted by tumor registries throughout the United States represents an esti-
mated 70% of newly diagnosed cancer cases. The authors analyzed NCDB reports
on ethnic distribution of patients with breast, prostate, nonsmall cell lung, and
colorectal cancer, stratified by stage of disease at diagnosis.
RESULTS. African Americans with cancer of the breast and prostate had the most
notable patterns of disproportionate representation among populations with ad-
vanced-stage disease. The authors compiled a table of suggested accrual targets for
selected solid-organ cancers based on NCDB stage-specific reports.
CONCLUSIONS. Clinical trial results will be more meaningful if participating pa-
tients reflect the site- and stage-specific populations that are under study. The
authors recommended that clinical trial investigators incorporate accrual targets
for minority ethnicity populations into the study design. Cancer 2006;106:188 –95.
© 2005 American Cancer Society.
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Well documented, but incompletely understood, disparities areobserved in cancer incidence and outcome among different
subsets of the American population identified by ethnicity and/or
race. Population-based survival data for breast, prostate, lung, and
colorectal cancer, as reported by the Surveillance, Epidemiology, and
End Results (SEER) Program are shown in Figure 1 and demonstrate
notably different mortality rates for some minority ethnicity groups
such as African Americans, Hispanic/Latino Americans, Native Amer-
icans/Alaskan Natives, and Asian Americans compared with White
Americans.1 Mortality risks from these solid-organ malignancies are
higher for patients that self-identify as having an African-American
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background. Racial and ethnic minority patients
(hereafter referred to as minority ethnicity) popula-
tions are disproportionately represented among the
uninsured and the impoverished (Table 1),2– 4 sup-
porting the contention that socioeconomic disadvan-
tages and barriers to healthcare access contribute to
these outcome disparities. As demonstrated by Ward
et al.,5 cancer outcomes are consistently worse among
socioeconomically deprived subsets within individual
ethnic groups, but poverty rates alone do not com-
pletely explain variations in cancer burden that are
observed among different ethnically defined popula-
tions. For example, rates of poverty and lack of health-
care coverage are similarly high among African Amer-
icans and Hispanic Americans/Latinos, yet reported
cancer mortality rates are lower for the latter group.
Other factors that may contribute to group-level mor-
tality differences include disparities in delivery of care,
primary ethnicity-related variation in tumor biology
and/or drug metabolism, and nutritional/dietary pat-
terns.
All of the issues described above are worthy of
targeted research; however, one question requiring
immediate attention is whether or not standard of
care treatment, as well as advanced, investigational
therapeutics, can be delivered equitably and with
comparable effectiveness to the diverse cancer popu-
lation in the United States. The clinical trial mecha-
nism should be the appropriate strategy for address-
ing this question. A well designed prospective,
randomized, clinical trial will ensure that cancer treat-
ments are delivered in a standardized fashion to a
balanced and representative sample of the cancer
population. The importance of achieving this balance
in clinical trial enrollment was acknowledged by the
National Institutes of Health (NIH) Revitalization Act
of 1993,6 which mandates that the NIH ensure accrual
rates of women and minorities onto Phase III clinical
trials in numbers that are adequate for analyses. How-
ever, there are no universal standards that define op-
timal accrual proportions. Investigators will typically
strive for as much diversity in their patient accruals as
possible, but success in this endeavor is typically lim-
ited by costs of outreach activities and the extent of
diversity in the local patient population where the
clinical trial is being offered.
Recent studies have emphasized the challenges of
accruing minority ethnicity patients onto cancer clin-
ical trials,7–16 with most protocols ultimately settling
for underrepresentation by these communities. Typi-
cally, trialists will use either general population demo-
graphics or overall cancer population profiles as
benchmarks for defining the optimal ethnic distribu-
tion of their study populations. Although it is clearly
difficult to achieve accrual patterns that reflect the
diversity of these larger populations, some overview
analysts have actually reported substantial success
when national experience with clinical trials is scruti-
nized. For example, one study13 reached the conclu-
sion that as a whole, NCI trials are racially and ethni-
cally representative of the American population,
which suggests equal access to NCI clinical trials. This
interpretation was based on the ethnic distribution of
99,495 participants accrued to NCI-sponsored coop-
erative group clinical trials in 1991–1994. Eighty-five
percent of these participants were White American;
9.6% were African American; and 5.6% were Hispanic/
Latino. These proportions are comparable to general
population demographics.
Ethnicity-related variations in incidence and stage
distributions for most cancers create a problem that is
integrally associated with the disproportionate mor-
tality burden that is observed. Extrapolating from gen-
eral census data to define accrual targets for cancer
clinical trials is, therefore, potentially misleading. For
example, African-American women have an overall
lower incidence of breast cancer compared with
White-American women, yet African-American
women are more likely to present with advanced
stages of disease. Clinical trials that evaluate promis-
ing treatments for high-risk disease should strive for
accrual rates that reflect the disproportionately high
volume of advanced-stage African-American breast
cancer patients. General population and overall breast
cancer patient population demographics will yield ac-
crual targets for African-American women that are
inappropriately low, as they would not account for the
actual profile of American women presenting with
advanced stage disease. The goal of this project is to
TABLE 1
Ethnic Distributiona of United States Population, Age 18 Years and
Older (Estimated Total Adult Population 209,128,094), and











White American 72.0 14.2 9.1
African American 11.2 19.4 24.9
Hispanic/Latino 11.0 32.8 22.6
American Indian/Alaska Native 0.7 23.8 25.7
Asian 3.7 18.3 12.6
Native Hawaiian/Pacific Islander 0.1 18.6 17.7
Data taken from U.S. 2000 census.2– 4
a Approximately 0.1% of population is characterized as Other, and 1.3% is categorized as belonging to
two or more groups.
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use data captured and recorded by the National Can-
cer Data Base (NCDB) for the purpose of defining
stage-specific clinical trial accrual targets that more
accurately reflect the burden of disease that charac-
terizes different subsets of the American population
based on ethnicity and race.
MATERIALS AND METHODS
The NCDB was established in 1989 as a nationwide
oncology database. It is maintained as a joint project
of the American Cancer Society and the Commission
on Cancer of the American College of Surgeons. Infor-
mation is submitted to the NCDB on an estimated 70%
of all newly diagnosed cases of cancer from approxi-
mately 1600 hospitals in 50 states (more than
1,000,000 cases per year). The dataset includes demo-
graphic, clinical, and health system data elements that
are needed to assess quality of care. Hospitals contrib-
uting tumor registry information to the NCDB have
cancer programs that are approved by the Commis-
sion on Cancer, and they are categorized as follows:
1. Community Hospitals Cancer Program (CHCP)
accessions are 100 – 649 cancer cases per year;
CHCPs compose 38% of Commission on Cancer-
approved programs.
2. Community Hospital Comprehensive Cancer Pro-
gram (COMP) accessions are at least 650 cancer
cases per year; COMPs compose 36% of Commis-
sion on Cancer-approved programs.
3. Teaching Hospital Cancer Program (THCP) must
be within a facility affiliated with a medical school
that participates in resident training in at least
four areas, two of which are medicine and surgery;
THCPs compose 22% of Commission on Cancer-
approved programs.
4. NCI-designated program Comprehensive Cancer
Program (NCIP) must take place within a facility
that is sponsored by an NCI peer-reviewed Cancer
Center Support Grant and is designated by the
NCI as a Comprehensive Cancer Center Program;
NCIPs compose 2% of Commission on Cancer-
approved programs.
5. Network Cancer Program (NCP) occurs within an
organization owning multiple facilities that pro-
vide integrated cancer care and offering compre-
hensive services; NCPs compose 1% of Commis-
sion on Cancer-approved programs.
6. Hospital Associate Cancer Programs, Affiliate Hos-
pital Cancer Programs, Integrated Cancer Pro-
grams, and Freestanding Cancer Center Programs
are outpatient and/or lower volume cancer pro-
grams; collectively they compose 1% of Commis-
sion on Cancer-approved programs.
We compiled information from the NCDB 2001 data
collections involving cancer of the breast, prostate,
lung (nonsmall cell), and colorectum. These collec-
tions involved information submitted on cancer pa-
tients from different hospitals as follows:
Breast Cancer: 159,193 cases from 1266 hospitals;
Prostate Cancer: 110,505 cases from 1261 hospitals;
Lung Cancer: 93,573 cases from 1271 hospitals;
Colorectal Cancer: 68,780 cases from 1268 hospitals.
We then evaluated the distribution of patients accord-
ing to ethnic background for each stage category. The
American Joint Commission on Cancer 5th edition
staging system was used, as this was the version in
effect during 2001, the year of data collection.17 Infor-
mation on patient ethnicity is recorded as submitted
by the tumor registries for the NCDB participating
hospitals and generally reflects self-reported data.
The decision was made before beginning the cur-
rent study to not test for statistical significance, as the
very large sample sizes would have resulted in signif-
icant values for absolute differences of relatively small
magnitude.
RESULTS
Tables 2–5 reveal ethnic distributions within disease
stage and total organ-specific cancer populations ac-
cording to NCDB reports on breast, prostate, lung, and
colorectal cancers, respectively. The most notable dis-
parities were seen for African Americans, who were
disproportionately overrepresented in advanced stage
categories.
Although African-American women accounted for
only 9% of all breast cancer cases in the United States,
they represented 14% and 15% of all Stage III and IV
breast cancer patients, respectively. In prostate can-
cer, African-American men represented 12.7% of pa-
tients affected, yet accounted for nearly 20% of all
Stage IV cases. Similar, but lesser magnitude, patterns
of disproportion were observed for nonsquamous cell
lung and colorectal cancer patient populations.
Proportions of other minority ethnicity subsets
within stage groupings for all four of the cancers eval-
uated were comparable to their proportions within the
total cancer population for each cancer. Hispanic/
Latino Americans are estimated to account for 3– 4%
of breast, prostate, and colorectal cancer populations,
and they account for similar proportions within stages
of these cancers. Hispanic/Latino Americans account
for 2.2% of all lung cancers recorded by the NCDB,
and they are estimated to represent 1.7–2.6% of the
Stage I–IV disease cases. Native Americans/American
Indians account for less than 0.5% of all cases and all
stages of breast, prostate, lung, and colorectal cancer.
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Asian Americans are estimated to account for 1.5–2.7%
of these cancers and their stage groups.
DISCUSSION
The NCDB reports reveal several disparities in propor-
tions of minority ethnicity patients presenting with
advanced stages of the most common solid-organ ma-
lignancies, such as breast, prostate, nonsquamous cell
lung, and colorectal cancer (Fig. 1). These patterns are
most notable for African Americans. We believe that
this disproportionate representation should be con-
sidered in the design of cancer clinical trials. Prospec-
tive planning of appropriate accrual “targets” for mi-
nority ethnicity patients will strengthen the likelihood
that trial results will be generalizable and meaningful
for the entire population of cancer patients. Ideally,
the study patient population will reflect the stage-
specific patient population for which the protocol is
designed.
Table 6 summarizes the ethnic distribution for
patients accrued onto various clinical trials as re-
ported by disease sites and accrual intervals. In con-
TABLE 2





















White American 83.1% 82.5% 86.8% 81.1% 77.3% 76.5%
African American 9.0% 9.1% 6.4% 10.4% 14.0% 15.2%
Hispanic/Latino American 3.4% 3.3% 2.7% 4.0% 4.8% 4.2%
Native American 0.1% 0.1% 0.1% 0.2% 0.2% 0.2%
Asian American 2.3% 2.7% 2.1% 2.3% 2.0% 2.0%
aProportions in each column do not sum to 100% because data for unknowns are not shown.
TABLE 3


















White American 79.9% 80.5% 80.4% 81.4% 71.9%
African American 12.7% 11.5% 12.4% 11.1% 19.6%
Hispanic/Latino American 3.7% 3.7% 3.6% 3.8% 4.7%
Native American 0.1% 0.2% 0.1% 0.2% 0.2%
Asian American 1.5% 2.1% 1.5% 1.5% 1.7%
aProportions in each column do not sum to 100% because data for unknowns are not shown.
TABLE 4


















White American 84.4% 87.7% 86.7% 83.7% 82.9%
African American 10.2% 8.0% 9.1% 11.0% 11.3%
Hispanic/Latino American 2.2% 1.7% 1.8% 2.3% 2.6%
Native American 0.2% 0.2% 0.1% 0.2% 0.2%
Asian American 1.7% 1.3% 1.2% 1.7% 2.0%
aProportions in each column do not sum to 100% because data for unknowns and in situ lesions are not shown.
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trast, Table 7 demonstrates some suggested accrual
targets for the four solid-organ malignancies that we
evaluated in the current study. These accrual targets
are based on assessment of overall organ site-specific
distributions of patients by ethnic background, as well
as stage-specific distributions within particular can-
cers. For advanced stages of cancer where a minority
ethnicity group is overrepresented, we recommend
that a protocol strive for an accrual that matches this
relatively higher proportion. For early stage disease,
where the minority ethnicity population is underrep-
resented, we recommend using the proportion con-
tributed by that group to the total cancer-specific pop-
ulation. Use of NCDB reports allows clinical trialists to
incorporate ethnicity-specific accrual targets into pro-
tocol design and to plan for adequate resources to
meet these goals. Focused NCDB reports can also
facilitate design of clinical trial accrual targets that
account for regional variation in cancer burden.
A few comments are necessary regarding the mi-
nority ethnicity populations that are evaluated in this
project. The terms Asian Americans and Pacific Island-
ers are frequently grouped together in reporting of
cancer statistics, and these population subsets are ac-
tually comprised of many different communities with
disparate languages, cultures, and ancestries. The
same is true for Native Americans/Alaskan Natives,
and Hispanic/Latino Americans. For the purpose of
streamlining accrual target recommendations, these
oversimplifications were used in this report also, and a
thorough review of issues that more accurately de-
scribe the heterogeneity of these populations is be-
yond the scope of this article. Clinical trial investiga-
tors should be cognizant of possible variations in
outreach needs for subsets within these communities,
based on linguistic issues, culture, and/or socioeco-
nomic differences.
The importance of ethnic diversity in the study of
human disease through clinical trials is not a new
concept, and it is certainly not limited to the study of
cancer. These issues, and the challenges of addressing
them, are apparent in medical literature concerning
cardiovascular diseases,18 –20 heart failure trials,21
mental health trials,22–24 and infectious disease stud-
ies,25 among others. Hussain-Gambles et al.9 provided
a concise list of barriers that prevent minority ethnic-
TABLE 5





















White American 82.4% 80.6% 84.5% 84.0% 81.5% 79.6%
African American 10.9% 12.5% 9.3% 9.4% 11.5% 13.4%
Hispanic/Latino American 3.0% 2.4% 2.8% 3.3% 2.9% 3.2%
Native American 0.2% 0.2% 0.2% 0.1% 0.2% 0.2%
Asian American 2.1% 2.3% 1.9% 1.8% 2.5% 2.2%
aProportions in each column do not sum to 100% because data for unknowns are not shown.
FIGURE 1. Five-year survival rates from breast, prostate, nonsmall cell lung, and colorectal cancer for White Americans, African Americans, and Hispanic/Latino
Americans. Data taken from SEER*Stat Database.1
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ity individuals from optimally using the clinical trials
mechanism. These barriers are
1. fear or mistrust,
2. inappropriate exclusion criteria,
3. poorly designed protocols,
4. inadequate access to clinical trials,
5. costs associated with interpretation or translation
services required for informed consent,
6. sociocultural barriers, and
7. stereotypes or cultural myths.
Overcoming these factors will require education and
behavior modification at both physician–provider and
patient levels. Patients must receive education on the
safety and advantages of clinical trial participation;
enrollment in a clinical trial is actually a safeguard that
ensures well monitored and standardized care that is
TABLE 6













Review of NCI-funded clinical trials
(1991–1994)
Breast 86.8 10.0 3.2 NR NR
Prostate 82.8 14.7 2.5 NR NR
Lung 88.7 9.8 1.4 NR NR




Breast NR 10 NR NR NR
Prostate NR 21 NR NR NR
Lung NR 13 NR NR NR
Colorectal NR 8 NR NR NR
Swanson et al.15
Literature review of treatment trials
(1973–1998)
90a 10.5 0.4 0.04  0.01
Sateren et al.13
Review of NCI-funded clinical trials
(1998–1999)




Breast 86.3 7.7 2.5 2.2 0.06
Lung 89.7 5.0 0.5 1.5 0.09
Colorectal 79.7 11.6 5.8 4.3 1.4
Murthy et al.11
Review of NCI-funded trials
(1996–2002)
Accrual by yr 1996 83.0 11.0 3.7 2.1 0.3
1999 86.0 9 3.0 1.5 0.5
2002 86.6 7.9 3.0 2.2 0.3
Accrual by site (2000–02) Breast 87.2 7.0 3.2 2.3 0.3
Prostate 80.3 15.5 2.3 1.3 0.2
Lung 89.7 7.4 1.4 1.3 0.3
Colorectal 87.8 6.9 3.1 1.9 0.3
NCI: National Cancer Institute; SWOG: Southwest Oncology Group; ACOSOG: American College of Surgeons Oncology Group.
a Estimated value based on reported data.
b 1.5% Asian American and 0.6% Hawaiian/Pacific Islander.
TABLE 7










Breast DCIS/Early-stage/Node-negative  11%  5%  3%  0.5%
LABC/Node-positive/Stage IV  14%  5%  3%  0.5%
Prostate Stages I–III nonmetastatic  12%  5%  2%  0.2%
Stage IV metastatic  19%  5%  2%  0.2%
Lung Stages I–III nonmetastatic  10%  2%  2%  0.2%
Stage IV metastatic  12%  2%  2%  0.2%
Colorectal Stages 0–II  10%  5%  3%  0.2%
Stages III/IV  12%  5%  3%  0.2%
DCIS: ductal carcinoma in situ; LABC: locally advanced breast cancer.
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free of physician bias and discriminatory practices in
delivery of care. Physicians must have knowledge of
the critical importance of ethnic and minority diver-
sity to the implementation of a meaningful clinical
trial. The physician must also resist the temptation to
assume that a patient will not be interested in a clin-
ical trial because of his or her ethnic background
and/or socioeconomic status.
Cultural competence26 must be apparent
throughout various stages of protocol design, initia-
tion, and interpretation of results. Unfortunately, sev-
eral investigators are reporting deficiencies in these
areas. Adams-Campbell et al.7 demonstrated inherent
barriers in clinical trial design that precluded African
Americans from being eligible to participate in clinical
trials in a Howard University study. Simon et al.14
reported that African-American breast cancer patients
were significantly less likely to be offered a clinical
trial compared with their White-American counter-
parts. Both investigators found that African Americans
had relatively high rates of trial participation if they
were eligible and if the trial was offered.
Issues pertinent to costs of clinical trial participa-
tion are also relevant. Whereas several studies have
demonstrated cost efficiency of clinical trials,27–29 a
facility that offers clinical trials must have an infra-
structure that can support the safe and well regulated
implementation of research protocols. A large propor-
tion of minority ethnicity patients receive routine
healthcare as well as cancer care through the so-called
“safety-net institutions,”, i.e., the publicly funded city
and county hospitals.30 Efforts to conduct clinical re-
search in these settings are often derailed by the over-
whelming burden of providing completely uncompen-
sated care to a patient population that has complex
and often long-neglected medical needs.
Several potential limitations of this study deserve
comment. The NCDB is a powerful resource, and its
magnitude suggests that it will accurately reflect cancer
patient populations of most practices. The NCDB was
not designed as a population-based registry, as was the
Surveillance, Epidemiology, and End Results (SEER) Pro-
gram. However, patterns of cancer patient demograph-
ics and stage distributions tend to be similar in reports
from the NCDB and the SEER databases, and it is, there-
fore, reasonable to assume comparable strength for the
two registries in reflecting the general cancer population
in the United States. Nonetheless, it is possible that
cancer information on a significant proportion of indi-
gent patients and, therefore, many minority ethnicity
patients is excluded from data collected by the NCDB,
because tumor registry data are voluntarily submitted by
participating institutions (Fig. 2).
Another limitation is that our accrual targets are
based on available current data, and cancer information
on some population subsets with rapidly changing de-
mographics will impact future clinical trial needs. For
example, SEER data as well as NCDB data indicate that
Hispanic Americans account for less than 5% of the
cancer population. The Hispanic-American community
is one of the most rapidly growing subsets of the Amer-
ican population, and it is projected to account for 24% of
the national population by the year 2050.31 We suggest
accrual targets of at least 5% for Hispanic Americans on
FIGURE 2. Stage distribution of breast, prostate, nonsmall cell lung (NSCLC), and colorectal cancer for White Americans, African Americans, and Hispanic/Latino
Americans.
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cancer clinical trials. Although this target is greater than
the average 2–3% accrued onto past trials, investigators
should consider the likelihood that Hispanic Americans
will compose a significantly larger proportion of future
cancer patient populations.
In summary, the challenge of achieving ethnic
balance and an appropriate degree of diversity in the
clinical trial patient population is a difficult one.
Nonetheless, it is a challenge that the oncology com-
munity is obligated to address. Otherwise, we will
never reach our ultimate goal of minimizing the threat
of cancer to the longevity of the individual as well as
the strength and productivity of the many communi-
ties that compose our society.
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